Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Praxis Precision Medicines, Inc. before investing.

In this article, we go over a few key elements for understanding Praxis Precision Medicines, Inc.’s stock price such as:

• Praxis Precision Medicines, Inc.’s current stock price and volume
• Why Praxis Precision Medicines, Inc.’s stock price changed recently
• Upgrades and downgrades for PRAX from analysts
• PRAX’s stock price momentum as measured by its relative strength

About Praxis Precision Medicines, Inc. (PRAX)

Before we jump into Praxis Precision Medicines, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company’s platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Want to learn more about Praxis Precision Medicines, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc.’s Stock Price as of Market Close

As of March 11, 2026, 3:59 PM, CST, Praxis Precision Medicines, Inc.’s stock price was $296.970.

Praxis Precision Medicines, Inc. is down 4.18% from its previous closing price of $309.910.

During the last market session, Praxis Precision Medicines, Inc.’s stock traded between $296.250 and $318.720. Currently, there are approximately 25.41 million shares outstanding for Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Praxis Precision Medicines, Inc. Stock Price History

Praxis Precision Medicines, Inc.’s (PRAX) price is currently down 11.81% so far this month.

During the month of March, Praxis Precision Medicines, Inc.’s stock price has reached a high of $342.510 and a low of $291.170.

Over the last year, Praxis Precision Medicines, Inc. has hit prices as high as $356.000 and as low as $26.700. Year to date, Praxis Precision Medicines, Inc.’s stock is up 0.76%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Praxis Precision Medicines, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 11, 2026, there were 0 analysts who downgraded Praxis Precision Medicines, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Praxis Precision Medicines, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Praxis Precision Medicines, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Praxis Precision Medicines, Inc. (PRAX) by visiting AAII Stock Evaluator.

Relative Price Strength of Praxis Precision Medicines, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 11, 2026, Praxis Precision Medicines, Inc. has a weighted four-quarter relative price strength of 107.60%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Praxis Precision Medicines, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Praxis Precision Medicines, Inc. Stock Price: Bottom Line

As of March 11, 2026, Praxis Precision Medicines, Inc.’s stock price is $296.970, which is down 4.18% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Praxis Precision Medicines, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.